At Next Breath, we value the importance of educating our clients on the latest technology and regulatory guidances. We make every effort that customer expectations match their deliverables. We review your requirements, answer your questions and develop a plan to meet your requirement with careful considerations to your budget before work begins. Below is a listing of some of the resources you can browse. If you have any questions about Next Breath’s services or would like to request a quote, please contact us.
Accelerate & de-risk programs including COVID-19, create differentiation & improve patient outcomes. Development of a New Chemical Entity and its commercialization requires up to 15 years work and can represent a $2.6 billion investment. Utilization of alternative dosage forms is a means to leverage that investment through life cycle management (LCM). In today’s fast changing global pandemic, repurposing a [...]
July 17, 2019 Key Learning Objectives CNS drug delivery opportunitiesNose-to-brain drug delivery challengesUtilization of animal models for CNS drug deliveryAdvantages of nasal dry powder delivery systems Audience R&DDrug DiscoveryProduct DevelopmentPackagingClinical DevelopmentSenior Scientist to Executives Register to Replay Webinar CNS PathwaysCurrently, there are more than 30 companies involved in the development of therapeutics for delivery to the brain via nasal deposition. [...]
If you are planning on submiting samples please download and submit the sample submission form.
This presentation examines SEM-EDS and Raman Spectroscopy as a means to accelerate generic drug applications. Presented on October 2017 at the 6th Medicon Valley Inhalation Symposium (MVIC) by Julie D. Suman, PhD.
This poster focuses on the utilization of the SPE© automated Raman spectroscopy system and its ability to measures the count, size and shape of particles, and chemical characterization.
This presentation examines global regulatory requirements along with regulatory approaches for bioequivalence and an overview of FDA drug specific guidance.